Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade (ICB)–based first line therapies in metastatic renal cell carcinoma (mRCC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rahul Winayak, Xinran Qi, Ali Moradi, Hedyeh Ebrahimi, Antonio Cruz Gomes, Miguel Zugman, Salvador Jaime-Casas, Xiaochen Li, Tanya B. Dorff, Joann Hsu, Alex Chehrazi-Raffle, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Peter P. Lee, Thomas P. Parks, Jennifer Karmouch, Robert R. Jenq, Sumanta Kumar Pal, Nazli Dizman
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162530686